Liver-directed gene-based therapies for inborn errors of metabolism

References

• Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 1994;6(4):335–341.
   PubMed Web of Science ®Google Scholar
• Kvittingen EA, Rootwelt H, Berger R, et al. Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest. 1994;94(4):1657–1661.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–2365.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994–2004.
   PubMed Web of Science ®Google Scholar
• George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215–2227.
   PubMed Web of Science ®Google Scholar
• Akache B, Grimm D, Pandey K, et al. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol. 2006;80(19):9831–9836.
   PubMed Web of Science ®Google Scholar
• Siew SM, Cunningham SC, Zhu E, et al. Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC Type 3 using hybrid AAV-piggyBac gene therapy. Hepatology. 2019;70(6):2047–2061.
   PubMed Web of Science ®Google Scholar
• Murillo O, Moreno D, Gazquez C, et al. Liver expression of a MiniATP7B gene results in long-term restoration of copper homeostasis in a wilson disease model in mice. Hepatology. 2019;70(1):108–126.
   PubMed Web of Science ®Google Scholar
• Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol. 2002;15(7):699–704.
   PubMed Web of Science ®Google Scholar
• Halpern KB, Shenhav R, Matcovitch-Natan O, et al. Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature. 2017;542(7641):352–356.
   PubMed Web of Science ®Google Scholar
• Bell P, Wang L, Gao G, et al. Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. Mol Genet Metab. 2011;104(3):395–403.
   PubMed Web of Science ®Google Scholar
• Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24(2):59–67.
   PubMed Web of Science ®Google Scholar
• La Bella T, Imbeaud S, Peneau C, et al. Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut. 2020;69(4):737–747.
   PubMed Web of Science ®Google Scholar
• Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol. 2016;21:75–80.
   PubMed Web of Science ®Google Scholar
• Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002;76(2):791–801.
   PubMed Web of Science ®Google Scholar
• Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99(18):11854–11859.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Gray JT, Ng CY, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2006;107(7):2653–2661.
   PubMed Web of Science ®Google Scholar
• Wang L, Calcedo R, Wang H, et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther. 2010;18(1):126–134.
   PubMed Web of Science ®Google Scholar
• Vercauteren K, Hoffman BE, Zolotukhin I, et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther. 2016;24(6):1042–1049.
   PubMed Web of Science ®Google Scholar
• Li S, Ling C, Zhong L, et al. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol Ther. 2015;23(12):1867–1876.
   PubMed Web of Science ®Google Scholar
• Wang L, Bell P, Somanathan S, et al. Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther. 2015;23(12):1877–1887.
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–378.
   PubMed Web of Science ®Google Scholar
• Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A. 2008;105(22):7827–7832.
   PubMed Web of Science ®Google Scholar
• Markusic DM, Herzog RW, Aslanidi GV, et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther. 2010;18(12):2048–2056.
   PubMed Web of Science ®Google Scholar
• Gabriel N, Hareendran S, Sen D, et al. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Hum Gene Ther Methods. 2013;24(2):80–93.
   PubMed Web of Science ®Google Scholar
• Sen D, Gadkari RA, Sudha G, et al. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods. 2013;24(2):104–116.
   PubMed Web of Science ®Google Scholar
• Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood. 2013;121(12):2224–2233.
   PubMed Web of Science ®Google Scholar
• Zinn E, Pacouret S, Khaychuk V, et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. 2015;12(6):1056–1068.
   PubMed Web of Science ®Google Scholar
• Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol. 2008;82(12):5887–5911.
   PubMed Web of Science ®Google Scholar
• Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 2007;25(8):903–910.
   PubMed Web of Science ®Google Scholar
• Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506(7488):382–386.
   PubMed Web of Science ®Google Scholar
• Paulk NK, Pekrun K, Zhu E, et al. Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity. Mol Ther. 2018;26(1):289–303.
   PubMed Web of Science ®Google Scholar
• Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996;7(17):2101–2112.
   PubMed Web of Science ®Google Scholar
• Maddalena A, Tornabene P, Tiberi P, et al. Triple vectors expand AAV transfer capacity in the retina. Mol Ther. 2018;26(2):524–541.
   PubMed Web of Science ®Google Scholar
• Trapani I, Colella P, Sommella A, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. 2014;6(2):194–211.
   PubMed Web of Science ®Google Scholar
• Kodippili K, Hakim CH, Pan X, et al. Dual AAV gene therapy for duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum Gene Ther. 2018;29(3):299–311.
   PubMed Web of Science ®Google Scholar
• Tornabene P, Trapani I, Minopoli R, et al. Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci Transl Med. 2019;11(492):492.
   Web of Science ®Google Scholar
• Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351–360.
   PubMed Web of Science ®Google Scholar
• Mamcarz E, Zhou S, Lockey T, et al. Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1. N Engl J Med. 2019;380(16):1525–1534.
   PubMed Web of Science ®Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341(6148):1233151.
   PubMed Web of Science ®Google Scholar
• Thompson AA, Walters MC, Kwiatkowski J, et al. Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia. N Engl J Med. 2018;378(16):1479–1493.
   PubMed Web of Science ®Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–855. .
   PubMed Web of Science ®Google Scholar
• Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630–1638.
   PubMed Web of Science ®Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158.
   PubMed Web of Science ®Google Scholar
• Milani M, Annoni A, Moalli F, et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci Transl Med. 2019;11:493.
   Web of Science ®Google Scholar
• Cantore A, Ranzani M, Bartholomae CC, et al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med. 2015;7(277):277ra228.
   Web of Science ®Google Scholar
• Roseman DS, Khan T, Rajas F, et al. G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a. Mol Ther. 2018;26(3):814–821.
   PubMed Web of Science ®Google Scholar
• An D, Schneller JL, Frassetto A, et al. Systemic Messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548–3558.
   PubMed Web of Science ®Google Scholar
• Prieve MG, Harvie P, Monahan SD, et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency. Mol Ther. 2018;26(3):801–813.
   PubMed Web of Science ®Google Scholar
• Truong B, Allegri G, Liu XB, et al. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc Natl Acad Sci U S A. 2019;116(42):21150–21159.
   PubMed Web of Science ®Google Scholar
• Cao J, An D, Galduroz M, et al. mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency. Mol Ther. 2019;27(7):1242–1251.
   PubMed Web of Science ®Google Scholar
• Balakrishnan B, An D, Nguyen V, et al. Novel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of classic galactosemia. Mol Ther. 2020;28(1):304–312.
   PubMed Web of Science ®Google Scholar
• Jiang L, Berraondo P, Jerico D, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018;24(12):1899–1909.
   PubMed Web of Science ®Google Scholar
• Zhu X, Yin L, Theisen M, et al. Systemic mRNA Therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates. Am J Hum Genet. 2019;104(4):625–637.
   PubMed Web of Science ®Google Scholar
• Nakai H, Yant SR, Storm TA, et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75(15):6969–6976.
   PubMed Web of Science ®Google Scholar
• Paulk NK, Wursthorn K, Wang Z, et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology. 2010;51(4):1200–1208.
   PubMed Web of Science ®Google Scholar
• Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011;475(7355):217–221.
   PubMed Web of Science ®Google Scholar
• Anguela XM, Sharma R, Doyon Y, et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood. 2013;122(19):3283–3287.
   PubMed Web of Science ®Google Scholar
• Huai C, Jia C, Sun R, et al. CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice. Hum Genet. 2017;136(7):875–883.
   PubMed Web of Science ®Google Scholar
• Ohmori T, Nagao Y, Mizukami H, et al. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep. 2017;7(1):4159.
   PubMedGoogle Scholar
• Guan Y, Ma Y, Li Q, et al. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med. 2016;8(5):477–488.
   PubMed Web of Science ®Google Scholar
• Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32(6):551–553.
   PubMed Web of Science ®Google Scholar
• Shao Y, Wang L, Guo N, et al. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats. J Biol Chem. 2018;293(18):6883–6892.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang L, Bell P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34(3):334–338.
   PubMed Web of Science ®Google Scholar
• Song CQ, Wang D, Jiang T, et al. In vivo genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency. Hum Gene Ther. 2018;29(8):853–860.
   PubMed Web of Science ®Google Scholar
• Shen S, Sanchez ME, Blomenkamp K, et al. Amelioration of Alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice. Hum Gene Ther. 2018;29(8):861–873.
   PubMed Web of Science ®Google Scholar
• Schuh RS, Poletto E, Pasqualim G, et al. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system. J Control Release. 2018;288:23–33.
   PubMed Web of Science ®Google Scholar
• Pan Y, Shen N, Jung-Klawitter S, et al. CRISPR RNA-guided FokI nucleases repair a PAH variant in a phenylketonuria model. Sci Rep. 2016;6:35794.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang Y, Breton C, et al. A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. Sci Adv. 2020;6(7):eaax5701.
   PubMed Web of Science ®Google Scholar
• Junge N, Yuan Q, Vu TH, et al. Homologous recombination mediates stable Fah gene integration and phenotypic correction in tyrosinaemia mouse-model. World J Hepatol. 2018;10(2):277–286.
   PubMed Web of Science ®Google Scholar
• Stephens CJ, Lauron EJ, Kashentseva E, et al. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9. J Control Release. 2019;298:128–141.
   PubMed Web of Science ®Google Scholar
• Barzel A, Paulk NK, Shi Y, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2015;517(7534):360–364.
   PubMed Web of Science ®Google Scholar
• Porro F, Bortolussi G, Barzel A, et al. Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model. EMBO Mol Med. 2017;9(10):1346–1355.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SR, Li LH, et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One. 2011;6(4):e18556.
   PubMed Web of Science ®Google Scholar
• Laoharawee K, DeKelver RC, Podetz-Pedersen KM, et al. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol Ther. 2018;26(4):1127–1136.
   PubMed Web of Science ®Google Scholar
• Sharma R, Anguela XM, Doyon Y, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood. 2015;126(15):1777–1784.
   PubMed Web of Science ®Google Scholar
• De Caneva A, Porro F, Bortolussi G, et al. Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. JCI Insight. 2019;5.
   Web of Science ®Google Scholar
• Conway A, Mendel M, Kim K, et al. Non-viral delivery of zinc finger nuclease mrna enables highly efficient in vivo genome editing of multiple therapeutic gene targets. Mol Ther. 2019;27(4):866–877.
   PubMed Web of Science ®Google Scholar
• Ou L, Przybilla MJ, Tăbăran AF, et al. A novel gene editing system to treat both Tay–Sachs and Sandhoff diseases. Gene Ther. 2020;27(5):226–236.
   PubMed Web of Science ®Google Scholar
• Ou L, Przybilla MJ, Ahlat O, et al. A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis Type I. Mol Ther. 2020;28(6):1442–1454.
   PubMed Web of Science ®Google Scholar
• Zhang JP, Cheng XX, Zhao M, et al. Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. Genome Biol. 2019;20(1):276.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530.
   PubMed Web of Science ®Google Scholar
• Wang L, Smith J, Breton C, et al. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. Nat Biotechnol. 2018;36(8):717–725.
   PubMed Web of Science ®Google Scholar
• Ding Q, Strong A, Patel KM, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014;115(5):488–492.
   PubMed Web of Science ®Google Scholar
• Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520(7546):186–191.
   PubMed Web of Science ®Google Scholar
• Wang X, Raghavan A, Chen T, et al. CRISPR-Cas9 Targeting of PCSK9 in human hepatocytes in vivo-brief report. Arterioscler Thromb Vasc Biol. 2016;36(5):783–786.
   PubMed Web of Science ®Google Scholar
• Yin H, Song CQ, Suresh S, et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017;35(12):1179–1187.
   PubMed Web of Science ®Google Scholar
• Ibraheim R, Song CQ, Mir A, et al. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol. 2018;19(1):137.
   PubMedGoogle Scholar
• Edraki A, Mir A, Ibraheim R, et al. A compact, high-accuracy Cas9 with a Dinucleotide PAM for in vivo genome editing. Mol Cell. 2019;73(4):714–726 e714.
   PubMed Web of Science ®Google Scholar
• Carreras A, Pane LS, Nitsch R, et al. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biol. 2019;17(1):4.
   PubMedGoogle Scholar
• Bjursell M, Porritt MJ, Ericson E, et al. Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates alpha1-antitrypsin Deficiency Phenotype. EBioMedicine. 2018;29:104–111.
   PubMed Web of Science ®Google Scholar
• Rossidis AC, Stratigis JD, Chadwick AC, et al. In utero CRISPR-mediated therapeutic editing of metabolic genes. Nat Med. 2018;24(10):1513–1518.
   PubMed Web of Science ®Google Scholar
• Pankowicz FP, Barzi M, Legras X, et al. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun. 2016;7:12642.
   PubMed Web of Science ®Google Scholar
• Pankowicz FP, Barzi M, Kim KH, et al. Rapid disruption of genes specifically in livers of mice using multiplex CRISPR/Cas9 editing. Gastroenterology. 2018;155(6):1967–1970 e1966.
   PubMed Web of Science ®Google Scholar
• Zabaleta N, Barberia M, Martin-Higueras C, et al. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nat Commun. 2018;9(1):5454.
   PubMedGoogle Scholar
• Wang D, Li J, Song CQ, et al. Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol. 2018;36(9):839–842.
   PubMed Web of Science ®Google Scholar
• Rees HA. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018;19(12):770–788.
   PubMed Web of Science ®Google Scholar
• Chadwick AC, Wang X. In vivo base editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a therapeutic alternative to genome editing. Arterioscler Thromb Vasc Biol. 2017;37(9):1741–1747.
   PubMed Web of Science ®Google Scholar
• Levy JM, Yeh WH, Pendse N, et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng. 2020;4(1):97–110.
   PubMed Web of Science ®Google Scholar
• Villiger L, Grisch-Chan HM, Lindsay H, et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat Med. 2018;24(10):1519–1525.
   PubMed Web of Science ®Google Scholar
• Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–471.
   PubMed Web of Science ®Google Scholar
• Song CQ, Jiang T, Richter M, et al. Adenine base editing in an adult mouse model of tyrosinaemia. Nat Biomed Eng. 2020;4(1):125–130.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Zhou R, Iyer S, et al. CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Nat Biotechnol. 2019;37(9):1041–1048.
   PubMed Web of Science ®Google Scholar
• Kim D, Lim K, Kim ST, et al. Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat Biotechnol. 2017;35(5):475–480.
   PubMed Web of Science ®Google Scholar
• Zhou C, Sun Y, Yan R, et al. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature. 2019;571(7764):275–278.
   PubMed Web of Science ®Google Scholar
• Pickar-Oliver A. The next generation of CRISPR–Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490–507.
   PubMed Web of Science ®Google Scholar
• Scott DA. Implications of human genetic variation in CRISPR-based therapeutic genome editing. Nat Med. 2017;23(9):1095–1101.
   PubMed Web of Science ®Google Scholar
• Haapaniemi E, Botla S, Persson J, et al. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24(7):927–930.
   PubMed Web of Science ®Google Scholar
• Ihry RJ, Worringer KA, Salick MR, et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939–946.
   PubMed Web of Science ®Google Scholar
• Enache OM, Rendo V, Abdusamad M, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020;52(7):662–668.
   Web of Science ®Google Scholar
• Charlesworth CT, Deshpande PS, Dever DP, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249–254.
   PubMed Web of Science ®Google Scholar
• Wagner DL, Amini L, Wendering DJ, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med. 2019;25(2):242–248.
   PubMed Web of Science ®Google Scholar
• Li A, Tanner MR, Lee CM, et al. AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9. Mol Ther. 2020;28(6):1432–1441.
   PubMed Web of Science ®Google Scholar
• Schmidt ST, Yu FB, Blainey PC, et al. nucleic acid cleavage with a hyperthermophilic Cas9 from an uncultured Ignavibacterium. Proc Natl Acad Sci U S A. 2019;116(46):23100–23105.
   PubMed Web of Science ®Google Scholar
• Finn JD, Smith AR, Patel MC, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22(9):2227–2235.
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815–825.
   PubMed Web of Science ®Google Scholar
• Butterfield JSS, Hege KM, Herzog RW. A molecular revolution in the treatment of hemophilia. Mol Ther. 2020;28(4):997–1015.
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519–2530.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ gene therapy for Hemophilia A. N Engl J Med. 2020;382(1):29–40.
   PubMed Web of Science ®Google Scholar
• Kattenhorn LM, Tipper CH, Stoica L, et al. Adeno-associated virus gene therapy for liver disease. Hum Gene Ther. 2016;27(12):947–961.
   PubMed Web of Science ®Google Scholar
• Ferla R, Alliegro M, Marteau JB, et al. Non-clinical safety and efficacy of an AAV2/8 vector administered intravenously for treatment of mucopolysaccharidosis Type VI. Mol Ther Methods Clin Dev. 2017;6:143–158.
   PubMed Web of Science ®Google Scholar
• Puzzo F, Colella P, Biferi MG, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase. Sci Transl Med. 2017;9:418.
   Web of Science ®Google Scholar
• Boutin S, Monteilhet V, Veron P, et al. prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–712.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick Z, Leborgne C, Barbon E, et al. Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV Vector Transduction. Mol Ther Methods Clin Dev. 2018;9:119–129.
   PubMed Web of Science ®Google Scholar
• George LA, Ragni MV, Rasko JEJ, et al. Long-term follow-up of the first in human intravascular delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. Mol Ther. 2020. DOI:https://doi.org/10.1016/j.ymthe.2020.06.001.
   Google Scholar
• Masat E, Pavani G. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med. 2013;15(85):379–389.
   PubMed Web of Science ®Google Scholar
• Meliani A, Boisgerault F, Hardet R, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun. 2018;9(1):4098. .
   PubMedGoogle Scholar
• Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377(5):442–453.
   PubMed Web of Science ®Google Scholar
• Leborgne C, Barbon E, Alexander JM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020;26(7):1096–1101.
   PubMed Web of Science ®Google Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342–347.
   PubMed Web of Science ®Google Scholar
• Nakai H, Montini E, Fuess S, et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003;34(3):297–302.
   PubMed Web of Science ®Google Scholar
• Huser D, Weger S. Kinetics and frequency of adeno-associated virus site-specific integration into human chromosome 19 monitored by quantitative real-time PCR. J Virol. 2002;76(15):7554–7559.
   PubMed Web of Science ®Google Scholar
• Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015;125(2):870–880.
   PubMed Web of Science ®Google Scholar
• Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317(5837):477.
   PubMed Web of Science ®Google Scholar
• Herzog RW. Encouraging and unsettling findings in long-term follow-up of AAV gene transfer. Mol Ther. 2020;28(2):341–342.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Rosales C, McIntosh J, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19(5):876–885.
   PubMed Web of Science ®Google Scholar
• Gil-Farina I, Fronza R, Kaeppel C, et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther. 2016;24(6):1100–1105.
   PubMed Web of Science ®Google Scholar
• Erez A, Shchelochkov OA, Plon SE, et al. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am J Hum Genet. 2011;88(4):402–421.
   PubMed Web of Science ®Google Scholar
• Weber ND, Odriozola L, Martinez-Garcia J, et al. Smerdou C: gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model. Nat Commun. 2019;10(1):5694.
   PubMedGoogle Scholar
• Aronson SJ, Bakker RS, Shi X, et al. Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice. J Hepatol. 2019;71(1):153–162.
   PubMed Web of Science ®Google Scholar
• Murillo O, Luqui DM, Gazquez C, et al. Long-term metabolic correction of Wilson’s disease in a murine model by gene therapy. J Hepatol. 2016;64(2):419–426.
   PubMed Web of Science ®Google Scholar
• Chakrapani A, Sivakumar P, McKiernan PJ. Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J Pediatr. 2002;140(2):261–263.
   PubMed Web of Science ®Google Scholar
• Vara R, Turner C, Mundy H, et al. Liver transplantation for propionic acidemia in children. Liver Transplant. 2011;17(6):661–667.
   PubMed Web of Science ®Google Scholar
• Jauze L, Monteillet L, Mithieux G, et al. Challenges of gene therapy for the treatment of glycogen storage diseases Type I and Type III. Hum Gene Ther. 2019;30(10):1263–1273.
   PubMed Web of Science ®Google Scholar
• SSIEM. 2019: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rotterdam, The Netherlands, 3-6 September 2019. J Inherit Metab Dis. 2019;42(Suppl 1):1–479.
   Google Scholar
• Blau N, van Spronsen FJ. Levy HL: phenylketonuria. Lancet. 2010;376(9750):1417–1427.
   PubMed Web of Science ®Google Scholar
• Skinner MW. Gene therapy for hemophilia: addressing the coming challenges of affordability and accessibility. Mol Ther. 2013;21(1):1–2.
   PubMed Web of Science ®Google Scholar